Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
Braveheart Bio priced IPO at $18 per share, raising $382.5M; Nasdaq debut Thursday (ticker BRVE). The cardiac biotech, founded 2024, develops BHB-1893—a myosin inhibitor licensed from Hengrui Pharma—competing against Camzyos; it's the 17th drugmaker IPO in 2026.
An article from
Dive Brief
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
Published Aug. 5, 2026
Travis Murdoch, the chief executive officer of Braveheart Bio, formerly led the team at HI-Bio.
Braveheart Bio shares surged 68% in their Nasdaq debut after a $382.5M IPO, pushing the cardiovascular biotech's market cap past…
Braveheart Bio files for a $318.8M IPO on Nasdaq backed by a16z Bio + Health, targeting a $1.2B valuation for its heart drug…
Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.
Braveheart Bio files for a $319M Nasdaq IPO backed by a16z Bio + Health, raising questions about how crypto's biggest VC…
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s…
Braveheart Bio prices $382.5M IPO, tapping Hengrui-licensed BHB-1893 to challenge Bristol Myers' Camzyos and Cytokinetics'…
